ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 168 filers reported holding ASCENDIS PHARMA A/S in Q1 2023. The put-call ratio across all filers is 0.19 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,687 | +53.3% | 285,000 | +46.2% | 17.16% | +36.8% |
| Q2 2023 | $17,404 | +64.7% | 195,000 | +97.8% | 12.55% | +69.6% |
| Q1 2023 | $10,569 | -42.8% | 98,571 | -34.9% | 7.40% | -17.4% |
| Q4 2022 | $18,492 | -99.9% | 151,409 | +4.3% | 8.95% | -22.1% |
| Q3 2022 | $16,699,000 | +49.7% | 145,209 | +21.0% | 11.49% | +32.8% |
| Q2 2022 | $11,155,000 | -40.8% | 120,000 | -25.2% | 8.65% | -25.0% |
| Q1 2022 | $18,836,000 | +20.8% | 160,500 | +38.5% | 11.54% | +222.7% |
| Q4 2021 | $15,590,000 | +46.6% | 115,885 | +73.7% | 3.58% | -59.6% |
| Q3 2021 | $10,634,000 | +62.6% | 66,714 | +34.2% | 8.85% | +93.7% |
| Q2 2021 | $6,541,000 | +87.5% | 49,721 | +83.7% | 4.57% | +415.7% |
| Q1 2021 | $3,488,000 | -9.8% | 27,064 | +16.7% | 0.89% | -67.5% |
| Q4 2020 | $3,866,000 | – | 23,183 | – | 2.72% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |